Dyadic International Inc, DE Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
64.8%projected annual EPS growth
Analyst Coverage
2analysts covering
FY EPS (est.)
-$0.14next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Financial Results Release | 12 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Quarterly Revenue Growth Quarterly182.3%Target: Maintain double-to-triple digit year-over-year growth driven by commercial product launches
Cash and Investment Grade Securities Quarterly6.6MTarget: Maintain sufficient runway to support commercialization and operations
Net Loss per Share (EPS) Quarterly-0.1Target: Narrow losses sequentially toward projected 2027 breakeven
Watch Items
- Nasdaq Listing Compliance (Minimum Bid Price Rule)Trigger: Share price remains below $1.00; deadline to regain compliance is December 15, 2026Action: Request a hearing before an independent Nasdaq panel to temporarily halt delisting and seek approval for a reverse stock split (ratio 2:1 to 10:1)
- Stockholders' Equity LevelTrigger: Negative stockholders' equity of $407,732 as of March 31, 2026 (below Nasdaq's $2.5 million minimum requirement)Action: Improve equity position through potential conversion of outstanding senior secured notes or new equity/licensing transactions
- Commercial Adoption of AlbuFree™ DX Recombinant Human AlbuminTrigger: Initial commercial sales and profit-sharing milestones from partner Proliant Health & BiologicalsAction: Monitor sales channels and track profit-share revenue contributions to quarterly financials
Research as of 20 Jun 2026